Mon, Jul 28, 2014, 11:00 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Forest Laboratories Inc. Message Board

mirror_world_man 81 posts  |  Last Activity: Jun 26, 2014 12:28 PM Member since: Mar 23, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mirror_world_man by mirror_world_man May 29, 2014 7:54 PM Flag

    Only marginally better than low priced bashers. At least some fund wants CYTK higher ..

  • mirror_world_man by mirror_world_man May 27, 2014 6:07 PM Flag

    Latest short interest is up .5MM ending May 15. I imagine shorty borrowed to dump, only to cover higher later.

  • Happened yesterday. maybe we are next.

    Sentiment: Strong Buy

  • Reply to

    This can't be good

    by jdust1948 May 27, 2014 3:30 PM
    mirror_world_man mirror_world_man May 27, 2014 4:26 PM Flag

    lol 1948. I was thinking the same thing watching the Lego trading graphs over the last few days. Nothing organic in there at all. Everyone is holding for the long term and watching the bots short circuit. Shorts cannot cover and have left themselves exposed.

    Sentiment: Strong Buy

  • after you short them you leave yourself just a little too
    The next three weeks of Rx leading into the OpX, including a four day weekend for many, should yield slightly depressed weekly TRx numbers in the next fortnight, together with the hacy sac short trading towards June 20. It should be beautiful time to buy for anyone looking to add or start a position.

    Sentiment: Strong Buy

  • mirror_world_man by mirror_world_man May 23, 2014 12:56 PM Flag

    i did best practice analysis of pharma sales teams, with the help of a very expensive statistician, across the country while in BP and one of the parameters we used was absolute call number, as what would happen with an extra sales force or two. One of the significant take homes was market share changes was relatively neutral with increased details after a minimum of ~8 calls per target per year. The surprise was large and small medical education events hosted by reps drove revenue in the high performance teams. Particularly physician workshops with a specialist. The more peer to peer and smaller product lunches that a company can do, the more those territories increased market share. More of these programs can be done with more reps in the field with a promotional budget and CME action plan.

    Sentiment: Buy

  • Reply to

    Upgrades from Major Brokerages Soon

    by eddavis2011 May 23, 2014 8:51 AM
    mirror_world_man mirror_world_man May 23, 2014 12:02 PM Flag

    looks like some covering right now. The trick is do they drop it again to cover more, etc?

  • mirror_world_man by mirror_world_man May 23, 2014 12:22 AM Flag

    I like Navideas decision to focus on generating revenue from LS to fund operating income. Slow down expansion of everything and do each thing one at a time deliberately, rightly, makes sense. Save the need for debt and dilution. This is not a race. What I don't like is being forced into a major paradigm shift like that by the likes of Wall Street manipulators who know nothing of how to run a real company and build something rather than feed on the loss of others. Since when can maggots that sit in front of their tablets and drive share price down interfere with real treatment for very sick patients. Alzeimers affects us all, even maggots. Even maggots have sisters, daughters and mothers, you want to inject blue die into them like some lab animal if they have cancer. I encourage everyone to buy with whatever pocket change they can. Soon only real investors will own a real company.

    Sentiment: Strong Buy

  • Community of Practice leaders will be paid honorariums for their consultative input and tell the Blum et al what they want to hear in exchange for future investigator initiated trials (IIT's). Patient advocacy groups will be told the risk/benefit of compassionate use, gov bodies will be honour meetings and ask for further studies. The consultative process will take the rest of the year and cost about $8 MM IMO. The phase 3 will start in Spring 2015 IMO, with FDA NDA in 2016 1H. My interpretation of this Pharma Talk..
    "We expect to be engaging in that process over the next several weeks to months. We want to talk to ALS experts, both those who treat patients for their overall disease progression as well as those that focus their pulmonary effects and measure pulmonologists who treat these patients understand how they interpret these data so it can help us reconcile them in light of what may be the plan looking forward. We also want to engage with regulatory parties and potential partners that we may point to the next steps with Tirasemtiv"

    Sentiment: Buy

  • mirror_world_man by mirror_world_man May 22, 2014 2:19 PM Flag

    It would be logical for BP to initiate a buy out of SGYP at the end of all Phase III , or more likely post FDA approval, when it has become derisked as per CHTP. A bird in the hand is worth two in the air and all that. If I was still working in the strategic business development dept of a BP company that is exactly what I would say to the BOD. The idea that it may be too expensive is legitimate, but it is worth the price later on. The other thing is models for BT binaries have changed significantly in the last few years. CHTP is a good example. It was manipulated downward post approval and a buy out occurred. Shorts are frantic trying to cover above the cement floor at the moment with that stock, and it is a real pleasure watching the bass turds squirm as an aside. If we assume a modest 35% pop on a buy out, then it is in Longs best interest to delay the buyout as long as possible, let things appreciate a bit, and generate a larger absolute value. There is no way this stock is worth current price post FDA approval. I can see things rise over to over $8 in Jan 2015. these prices are sic.

    Sentiment: Strong Buy

  • or at least make it to 3

  • Reply to

    Navb new symbol

    by longtermholds May 22, 2014 8:32 AM
    mirror_world_man mirror_world_man May 22, 2014 11:21 AM Flag

    new symbol should be B U Y

  • Reply to

    Where is the supposed pre pdufa run up

    by neopnavbtrader May 21, 2014 3:27 PM
    mirror_world_man mirror_world_man May 21, 2014 4:17 PM Flag

    Manipulated BT's with high potential and also with high short interest don't have run ups anymore. The shorts dump a lot of shares to flatline the price pre binary and do bear raids to get cheap shares. The plague of shorts will need to cover and they cannot do it because nobody is selling. So they drop the price to pick up minute quantities of stop limits. The more the longs buy and hold the more trapped they become, particularly now with no promise of future placements or offerings. They are a one trick pony, all they know how to do is sell into any PR. They have no clue how to cover. So they play the waiting game, cover a tiny bit, and pay carrying costs. Meanwhile LS grows every quarter. I have plenty of powder and buy at every new dip, sold none yet. The more it drops the more I buy.

    Sentiment: Strong Buy

  • mirror_world_man by mirror_world_man May 21, 2014 2:34 PM Flag

    changed it to market price and got some more at 1.369. The games they

    Sentiment: Buy

  • Reply to

    June 21 Options

    by go4two2001 May 21, 2014 11:19 AM
    mirror_world_man mirror_world_man May 21, 2014 11:39 AM Flag

    june 7's call purchase could be a short incremental cover

  • Stock won't go down by itself so the shorts orchestrated their own manipulation dance. I got my buy orders in the $1.28.

    Sentiment: Strong Buy

  • mirror_world_man by mirror_world_man May 19, 2014 10:46 PM Flag

    so this is how the shorts try to cover 8MM shorts with a cement floor, hacky sac...boring

    Sentiment: Hold

  • hey, remember these guys, lol

  • Reply to

    Two sNDA dates near

    by aboutstx May 16, 2014 5:35 PM
    mirror_world_man mirror_world_man May 17, 2014 5:57 PM Flag

    More like the shorts are penalizing investors (and themselves) by manipulating the stock price to try to cover after betting against all positive binaries, starting with FDA approval last year.. They are the only ones trading alongside the MM's. I did like adding 20% exposure under 1.38 though, so I am not really complaining. The action plan of penetrating large oncology centers of excellence (that do their radionukes) not covered by Cardinal is a sign of maturity and marketplace understanding that comes with market research and experience. First new agent in a long time requires new understanding of patterns of practice in the medical field, its not like bringing a new product class to the mature diabetes market where the rigorous market research has been competed already...Targeting the centers that bring in the most volume is still a learning process, and NAVB is onto it.

    Sentiment: Strong Buy

  • mirror_world_man mirror_world_man May 17, 2014 4:14 PM Flag

    combined therapies in North America generally are not prescribed unless patients are stable and controlled on the individual components. It takes about 240 days on average for example before any combined product is used for the usual diabetic patient, regardless of proven evidence suggesting patients reach durable HbA1c goals quicker with combinations. Doctors like the flexibility of titrating individual components if needed, or stopping one of the drugs due to AE's.

    Sentiment: Strong Buy

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.